ZURA · Program file
tibulizumab
When did Zura Bio Ltd say tibulizumab results would come?
On , Zura Bio Ltd wrote in its SEC Form 8-K: “Topline data expected from HS and SSc Phase 2 studies in Q4 2026 and H1 2027, respectively” (Source)
Days left in the window the company stated: 73 · company’s wording: “Q4 2026”
Last checked: .
Watch this program: confirm your email to start one daily alert digest.
Program file
- Name as filed
- tibulizumab
- Other names in filings
- ZB-106
- Indication in the filing
- hidradenitis suppurativa (HS)
- Trials named in the same filing
- None listed
- Latest timing wording
- “Topline data expected from HS and SSc Phase 2 studies in Q4 2026 and H1 2027, respectively”
- Source
- 8-K · filed · SEC accepted · accession 0001104659-26-097526 · SEC original
- Last checked
Program ZURA-tibulizumab.